<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911104-0149</DOCNO><DOCID>911104-0149.</DOCID><HL>   Unimed Is Licensing   Its Anti-Nausea Drug   To Korea's Keun Wha</HL><DATE>11/04/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B10H</SO><CO>   UMED</CO><MS>CONSUMER NON-CYCLICAL (NCY)</MS><IN>DRUG MANUFACTURERS (DRG)</IN><NS>LICENSING AGREEMENTS (LIC)</NS><GV>FOOD AND DRUG ADMINISTRATION (FDA)</GV><RE>FAR EAST (FE)NEW JERSEY (NJ)NORTH AMERICA (NME)PACIFIC RIM (PRM)SOUTH KOREA (SK)UNITED STATES (US)</RE><LP>   SOMERVILLE, N.J. -- Unimed Inc. said it signed a licensingand supply agreement with Keun Wha Pharmaceutical Co. ofSeoul, South Korea, for Unimed's Marinol anti-nausea drug forcancer chemotherapy patients. Terms weren't disclosed.   Under the agreement, Keun Wha will finance certainclinical work and obtain product registration for Marinol inSouth Korea. It also will pay Unimed a licensing fee atregistration. It said it expects Keun Wha to file the productregistration in a few months, with approval expected betweenone and two years after that.</LP><TEXT>   Harold J. Tenoso, Unimed's chairman, said in a statementthat the agreement is the company's first Asian alliance forMarinol, its brand of dronabinol. Charles Harrison, Unimedpresident, said that the drug is approved and currently beingused in the U.S., Canada and Israel, and that the company hasalliances in Spain and Portugal with companies seekingapproval in those markets.   Unimed noted that Marinol is undergoing U.S. clinicaltrials for appetite stimulation and weight-loss prevention inAIDS patients. It added that the Food and Drug Administrationhas granted Marinol orphan-drug status for those uses whenmarketing approval is granted.</TEXT></DOC>